Stay updated with breaking news from Selective Targeting. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences - November 22, 2022 - read this article along with other careers information, tips and advice on BioSpace
WuXi will provide Coherent Biopharma with integrated CMC services to accelerate its present and future drug candidates (small molecule, peptide, oligonucleotide, and complex chemical conjugate, etc.), from API to drug product. This will include but not be limited to process development, manufacturing, analytical, and regulatory filing support. Peptide drug conjugates will be a focus of the partnership.
WuXi will provide Coherent Biopharma with integrated CMC services to accelerate its present and future drug candidates (small molecule, peptide, oligonucleotide, and complex chemical conjugate, etc.), from API to drug product. This will include but not be limited to process development, manufacturing, analytical, and regulatory filing support. Peptide drug conjugates will be a focus of the partnership.
/PRNewswire/ -- Armed with a novel strategy they developed for bolstering the body's immune response, scientists at Albert Einstein College of Medicine have...
/PRNewswire/ -- Armed with a novel strategy they developed for bolstering the body's immune response, scientists at Albert Einstein College of Medicine have...